ArticleInternational journal of clinical and experimental pathology2018
CyclinD1 promotes lymph node metastasis by inducing lymphangiogenesis in human ovarian carcinoma.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Biejiajian Pill Inhibits Carcinogenesis and Metastasis via the Akt/GSK-3β/Snail Signaling Pathway in Hepatocellular Carcinoma.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS AND
backgroundCyclinD1 regulates the G1/S phase transition of the cell cycle and is frequently overexpressed in many types of human cancers. Much evidence has implicated that the expression of CyclinD1 is related to the lymphatic metastasis of human ovarian carcinoma. However, the mechanism of CyclinD1 in lymphatic metastasis of ovarian carcinomas is still unclear. The objective of the present study was to assess the incidence of CyclinD1 expression in ovarian carcinomas and look for its correlation with lymph vessel density (LVD) and clinicopathological variables.
methodsWe assessed the expression of CyclinD1 levels and lymph vessel density (LVD) quantified through D2-40 by immunohistochemistry from 110 Chinese patients with primary ovarian carcinomas and 40 with benign ovarian tumors as controls.
resultsCyclinD1 was detected in 52 primary ovarian carcinomas (47.3%), which was significantly higher than its expression in the benign ovarian tumors. CyclinD1 expression was correlated with tumor grade, FIGO stage, T stage and lymphatic metastasis. Moreover, the LVD counts in the group of CyclinD1 positive expression were higher than in the group of CyclinD1 negative expression.
conclusionsOur findings indicate that CyclinD1 might be involved in lymph node metastasis by inducing lymphangiogenesis in human ovarian carcinoma.
Indexed as
Identifiers
31949756PMC6962868W3007870610What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.